Pharmaceutical intermediates
Palbociclib Intermediates
7 pharmaceutical intermediates for Palbociclib. Indication: Breast Neoplasma.
About Palbociclib
- Originator
- Pfizer Inc
- Indication
- Breast Neoplasma
- Approved Date
- 02/03/2015
- DS/DP
- 03/05/2027
Available intermediates
7 intermediates currently listed for Palbociclib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine | 733039-20-8 | / | / |
| 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one | 1013916-37-4 | / | / |
| 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one | 1016636-76-2 | / | / |
| tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate | 571188-59-5 | / | / |
| Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate | 571189-16-7 | / | / |
| tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate | 866084-31-3 | / | / |
| PD 0332991 HCl | 827022-32-2 | / | / |
Building toward Palbociclib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →